| INTRODUCTION
Peppermint is a perennial flowering plant that grows throughout Europe and North America. Peppermint (Mentha 9 piperita) is a (usually) sterile hybrid mint, a cross between Water mint (Mentha aquatica) and Spearmint (Mentha spicata) that is believed to have arisen naturally. Mint plants have a long history of medicinal use, dating to ancient Egypt, Greece, and Rome where they were used as stomach soothers. 1 Peppermint oil is obtained by steam distillation from the fresh leaves of peppermint. 2 Our goal was to review the literature on peppermint oil regarding its metabolism, effects on gastrointestinal physiology, clinical use and efficacy and safety.
| ME TH ODS
A PubMed literature search was performed using the following terms individually or in combination: peppermint, peppermint oil, pharmacokinetics, menthol, oesophagus, stomach, small intestine, gall-bladder, colon, transit, dyspepsia, nausea, abdominal pain and irritable bowel syndrome. Full manuscripts evaluating peppermint oil that were published through 15 July 2017 were reviewed. References from the selected manuscripts also were searched for additional relevant publications. A total of more than 2800 references were initially reviewed. Following removal of references overlapping between searches and those lacking original data, the authors agreed on inclusion of the 96 on which to base the information presented within this manuscript. When evaluating therapeutic trials for clinical disorders (eg, irritable bowel syndrome), only randomised placebo controlled trials were included.
3 | RESULTS
| Pharmacokinetics
Pharmacokinetic data relating to peppermint oil in humans are limited. 3 The main constituent and active ingredient of peppermint oil appears to be menthol although it contains a large number (greater than 80) of other components. 3, 4 Studies in rats and limited data in humans demonstrate that peppermint oil is rapidly absorbed. 3, 5, 6 However, when taken in capsule form designed for delayed-release, approximately 70% reaches the colon. 5 Though done in a small study (n = 13), delayed release formulations of peppermint oil (vs nondelayed-release formulations) altered menthol urinary pharmacokinetics by increasing the apparent lag time and time to peak plasma concentrations. The delayed-release formulation did not alter the absorption half-life or total area under the curve. 6 In healthy adults, an oral dose of 100 mg of menthol results in an average peak blood concentration of 16.7 AE 5.5 lmol/L and an apparent elimination t 1/2 of 56 AE 8 min. 7 However, as noted, pharmacokinetics are greatly dependent on the formulation used. 6 A L-menthol preparation sprayed directly onto the gastric mucosa was rapidly absorbed with peak concentrations reached within 1 hour after administration. 8 In addition, development (reflected by age) may impact the pharmacokinetics of menthol as we showed in a pilot study in healthy children administered peppermint oil. 3 Menthol is primarily metabolised in the liver via hepatic microsomal P450 enzymes and subsequently undergoes biotransformation via UDP-glucuronosyltransferases. 2, 3 Menthol is excreted into bile as menthol glucuronide. 3, 5 In particular, data show the importance of both CYP2A6 (the major P450 enzyme involved in menthol hydroxylation) and UGT2B7 expression in determining menthol clearance. 9, 10 Therefore, there is the potential for pharmacogenomics and other substances which impact either CYP2A6 or UGT2B7 activity to alter peppermint oil's concentration-time curve. Following biliary excretion, menthol glucuronide undergoes enterohepatic circulation. Peppermint oil metabolites are excreted in the urine in part as glucuronic acid conjugates with ≥50% of a 100 mg oral dose of menthol appearing in urine as menthol glucuronide. The degree to which the other gastrointestinal effects of peppermint oil contribute to its clinical benefit remains unclear (Figure 1 ).
| Effects on gastrointestinal tract neuromotor function
Evidence suggests that peppermint oil acts as a smooth muscle relaxant. 3 Hawthorn et al showed in guinea pig ileal smooth muscle in vitro that both peppermint oil and its constituent menthol were capable of blocking calcium channels. 12 In vitro studies using guinea pig colon and rabbit jejunum smooth muscle suggest peppermint oil reverses acetylcholine induced contraction and antagonises serotonin-induced contraction through calcium channel blockade. 13 Amato et al, using samples obtained at the time of surgery, observed that menthol induces circular smooth muscle relaxation in human colon by directly inhibiting contractility through the blockade of Ca • Adults with diffuse oesophageal spasm (n = 8)
• Oesophageal manometry at baseline then 10 min after PMO • Five drops of 11% PMO (presumably~25 mg) in 10 mL water
• No effect on LES or oesophageal body pressure • PMO decreased simultaneous oesophageal contractions in all patients (P < 0.01) and increased propagated body contractions (P < 0.01); decreased contraction variability • Two of eight had improvement in chest pain • Healthy adults: 21-23 y, n = 10; 35-45 y, n = 10; and adults with dyspepsia (n = 6).
• Solid meal gastric emptying scintigraphy at baseline and after 0.2 mL PMO
• Overall PMO-induced acceleration of gastric emptying (T1/2 ) in both groups • Adult patients undergoing endoscopy (n = 100)
• Double-blind randomised study comparing 20 mg intramuscular hyoscine (n = 50) to 20 mL of 1.6% PMO sprayed twice around pyloric ring (n = 50) • Subgroup completed electrogastrography (EGG) (n = 20) • Endoscopy videotaped with both maximal and minimal pyloric ring diameter measured to calculate opening and contraction ratios during 4 min assessment.
• Maximal opening ratio and was greater after PMO (P < 0.0001) • Contraction ratio was smaller after PMO (P < 0.0001) • Time required for disappearance antral contraction rings shorter in PMO (97.1 AE 11.4 s) vs hyoscine (185.9 AE 10.1 s; P < 0.0001) • EGG: Peak power frequency 2 min after PMO administration decreased to 2 cycles per minute and resolved within 11.5 AE 0.8 min
Goerg
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• Healthy adult volunteers (n = 12)
• 90 mg PMO (0.1 mL) or 50 mg caraway oil vs control (0.9% sodium chloride) vs 10 mg cisapride vs 10 mg butylscopolamine • 400 mL apple juice given • Ultrasound assessment of gastric and gall-bladder emptying based on cross-sectional areas and gallbladder emptying
• No effect of PMO vs placebo on gastric antrum cross-sectional area • Increased gall-bladder cross-sectional area following PMO vs placebo (44 AE 14% increase)
Micklefield
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• Healthy volunteers (n = 24)
• MO: 90 mg and caraway oil infused into the duodenum • Gastroduodenal manometry
• During Phase I and II: PMO decreased stomach corpus contractions (P = 0.042); no effect on antrum • During Phase III: PMO decreased frequency of contractions (particularly within the duodenum)
Mizuno
44
• Adult patients undergoing double contrast upper barium study (n = 420)
• Nonrandomised, (n = 205) given PMO: 10 mL of 1.6% solution and (n = 215) given water • Degree of spasm for lower stomach blindly scored (0-3 range, indicating none to severe)
• Less stomach spasm in PMO group vs Controls: 1.20 AE 0.05 vs 1.42 AE 0.11 (P < 0.001) | 741
| Antimicrobial/antifungal actions
Multiple studies have shown that peppermint oil (menthol) is one of the most potent antimicrobial/antifungal/anti-viral botanicals. 23 Peppermint oil is active against obligate and facultative anaerobes. 24 It also is bactericidal to at least 20 common enteric pathogens including Helicobacter pylori, Escherichia coli, Staphylococcus aureus, Klebsiella sp., Salmonella typhi, Shigella boydii, and Shigella flexneri.
25-28
More recently it has been shown that menthol can inhibit quorum sensing activity of gram-negative pathogens. 29 Peppermint oil also appears to have activity against fungal pathogens. 30 In a mouse model, a combination of menthol and menthone were effective in reducing the number of Schistosoma mansoni eggs in the faeces, liver, and intestine and reducing the number of hepatic granulomas. 31 
| Effects on inflammation
Studies demonstrate that peppermint oil (menthol) possesses antiinflammatory activity. 32 Oral administration of peppermint oil prevents both xylene induced gut inflammation in mice and acetic acid induced colitis in rats. 16, 32 In vitro, menthol suppresses the production of inflammatory mediators from human monocytes. 33 Immune cells also contain transient receptor potential cation channels. It is believed that the anti-inflammatory effects of peppermint oil may be
• Healthy volunteers (n = 13)
• Randomised crossover study in healthy volunteers • 182 mg PMO vs placebo with 50 mL water when fasting followed by nutrient drink given via pump over 60 min • Epigastric symptoms and satiation rated (n = 5) and/or barostat (n = 6) (with a total of n = 7 doing both) measured intragastric pressure before and after nutrient drink
• PMO decreased intragastric pressure (P < 0.0001) and gastric motility index (P < 0.05) during fasting • Did not affect parameters during the nutrient drink or gastric accommodation • Did not affect epigastric symptoms or satiation, gastric compliance, or sensitivity • Reduced appetite vs placebo during fasting Unless otherwise indicated data are presented as mean AE SD. • Healthy adults (n = 6)
• Gastroduodenal manometry to measure migrating motor complex • Enteric vs non-enteric coated PMO (90 mg) combined with caraway oil (50 mg)
• Increase in duodenal contractions with enteric-vs non-enteric coated capsules 
| Effects on behaviour
Studies in humans demonstrated that inhalation of peppermint aroma improves attention but whether it improves mood remains unclear. [36] [37] [38] Studies in rodents, which suggest menthol has dose dependent anxiolytic effects, implicate involvement of dopamine pathways. [39] [40] [41] Given the potential role of psychosocial distress in the expression of functional gastrointestinal pain disorders symptoms, this may be another potential mechanism of action.
| Peppermint oil effects on gastrointestinal physiology
Some older studies examining the physiological effects of peppermint oil describe the administration of "drops" rather than a milligram dosage. Thus, the actual dose of peppermint oil can only be estimated. Our calculations are based on 20 drops/mL and a presumed concentration of 916 mg of peppermint oil per mL. 42 A caveat regarding this assumption is the recognition that concentrations may vary as a result of botanical source and/or preparation of the peppermint oil. • Healthy subjects (n = 6)
• Open label randomised to 0.2 mL PMO or placebo • Given 0.5 mg neostigmine and 15 min later motility measured by triple lumen motility catheter
• PMO inhibited motor activity for a mean of 12 min (P < 0.05 vs placebo) Taylor   87 • Healthy subjects (n = 14)
• Given either PMO 0.2 mL (n = 6) or 0.1 mL citral (found in citrus oils) (n = 8) following stimulation of motility by neostigmine • Rectosigmoid motility measured using triple lumen tube
• Complete inhibition of motor activity by both oils Rogers 88 • Healthy subjects (n = 5)
• Given neostigmine to simulate motility followed 30 min later by cross-over of PMO 0.1 mL in 20 mL normal saline vs placebo (saline) • Distal colonic manometry
• 4/5 subjects had cramps/pain/urge to defecate after PMO associated with high amplitude (150-390 mm Hg) pressure waves • Activity (motility) index with PMO > placebo Sparks 58 • Adult patients undergoing barium enema (n = 141)
• Double-blind study with randomisation to PMO (30 mL placed in the barium and 10 mL in the enema tube; n = 70) or barium alone (n = 71) • Incomplete studies (n = 3) and those receiving hyoscine (n = 14) subsequently excluded (Table 2) Mizuno et al in the same study which evaluated oesophageal motor function using double contrast barium studies found peppermint oil given orally decreased spasms of the lower stomach. 44 During oesophagogastroduodenoscopy, investigators have found that peppermint oil/menthol sprayed on the mucosa decreased gastric peristalsis and increased pyloric ring diameter. 46, 47 Topical mucosa application is potentially appealing because systemic exposure to menthol is much reduced compared with oral administration.
2,6,8
Peppermint oil sprayed on the mucosa during oesophagogastroduodenoscopy was found to decrease peak power frequency on electrogastrography. 48 Manometry and/or barostat studies have identified the following peppermint oil effects: decreased intragastric pressure, decreased gastric motility index, no effect on gastric accommodation. [49] [50] [51] In healthy volunteers, peppermint oil taken orally did not affect epigastric symptoms or satiation though there was decreased appetite (vs placebo) during the fasting period. 50 The effect of peppermint oil on gastric emptying has been evaluated with mixed results. Using a test meal of solids and nuclear • 4 groups: Group 1, 20 mL 1.6% PMO to papilla (n = 10); Group 2, 40 mL 1.6% PMO to antrum and papilla (n = 9); Group 3, 20 mL 3.2% PMO to papilla (n = 10); Group 4, 20 mL 3.2% PMO to antrum and papilla (n =
• Nonsignificant reduction in duodenal contractions with PMO (6.1 AE 3.8 to 4.4 AE 2.9 per minute, P = 0.39) with no differences between groups
Shavakhi
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• Adult patients undergoing colonoscopy (n = 65)
• Double-blind randomised study 
T A B L E 6 Peppermint oil (PMO) randomised double-blind controlled trials for adult irritable bowel syndrome (IBS)
Reference Population Design Findings Adverse Events
Rees
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• Adults with IBS (n = 18); 2 withdrawals
• Double-blind cross-over trial comparing PMO 0.2 mL 1-2 caps TID vs placebo 9 3 weeks • Primary objective: Overall symptoms graded from on 5-point scale (+2 to À2 being excellent to terrible)
• More subjects had excellent or good outcomes while on PMO vs placebo [9 (50%) vs 2 (12.5%)], P < 0.01
• PMO with heartburn, n = 2
Dew
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• Adults with IBS (n = 29)
• Double-blind crossover multicenter study comparing PMO 0.2 mL 3-6 caps/d vs placebo 9 2 weeks
• Primary objective: Severity of daily abdominal symptoms (graded 0-3; asymptomatic to severe)
• More subjects (12/29) on PMO vs Placebo (3/29) with excellent or good overall abdominal symptoms (P < 0.001)
•Not reported Nash 66 • Adults with IBS (n = 41) with pain as a major symptom; 8 withdrawals: 6 failed to complete diary cards and 2 because of nausea and vomiting with PMO
• Double-blind crossover study:
PMO 0.2 mL 2 caps TID vs placebo 9 2 weeks each • Primary outcome: Daily pain recorded on visual analogue scale and 4 category scale (0-3; "no pain" to "a great deal of pain")
• No difference in primary outcomes (raw data not presented)
• PMO with nausea/ vomiting, n = 2 • PMO with heartburn, n = 6 Table 3 • "Heartburn or belching either did not occur or if it did was minimal" (unclear which group) • Slight burning during defecation, n = 5 (unclear which group) Liu 91 • Adults with IBS (n = 110); 9 withdrawals
• Double-blind parallel group study: PMO 187 mg TID to QID (n = 52) or placebo (n = 49) • PMO with heartburn, n = 1; skin rash, n = 1 • Adults with Rome II IBS (n = 57)
• Double-blind parallel group study: PMO 225 mg 2 caps BID (n = 24) vs placebo (n = 26) 9 4 weeks • Primary objective: Remission of IBS symptoms (>50% improvement of the overall IBS symptom
• 18 (75%) of the patients in the PMO group vs 10 (38%) placebo had a >50% reduction in total IBS symptoms score at week 4 (P < 0.01).
• 13 (54%) PMO subjects vs 3 (11%) placebo subjects had a >50% reduction in total IBS
• PMO with prolonged heartburn, n = 1 taken orally with water accelerated gastric emptying in both healthy adults and adults with dyspepsia. 52 In contrast, Goerg et al used ultrasonography to demonstrate peppermint oil (taken orally in a non-enteric capsule) had no effect on gastric emptying of liquids (apple juice). 53 Studying healthy adults via 3.3.3 | Peppermint oil effects on small bowel physiology and transit time (Table 3 )
Peppermint oil appears to decrease small bowel contractility. The double contrast barium study by Mizuno et al also demonstrated that the oral peppermint oil solution (vs. water) decreased spasm in the duodenal bulb. 44 Micklefield et al found that duodenally instilled peppermint oil decreased duodenal contractions during phase III (but not phase I or II) of the fasting period. 51 Investigators using peppermint oil instilled into the duodenum during endoscopic retrograde cholangiopancreatography noted subjective decreases in duodenal contractions and a trend for an overall decrease in duodenal contractions per minute. 54, 55 As might be anticipated, the timing of the effect of peppermint oil on duodenal contractility appears related to the peppermint oil formulation used. Using manometry Micklefield and colleagues using an enteric (vs non-enteric) coated peppermint oil (both mixed with caraway oil) given orally noted that the decrease in duodenal contractions occurred later in the enteric vs the non-enteric coated preparation. 49 Based on hydrogen breath testing, peppermint oil has been found to slow orocaecal transit. 53 Wildgrube et al used carmine red to demonstrate that peppermint oil slowed whole intestinal transit. symptoms score at week 8 (P < 0.01).
Merat 94
• Adults with Rome II IBS (n = 90); 30 withdrawals
• Double-blind parallel group study of PMO 187 mg (0.2 mL) TID (n = 27) vs placebo (n = 33) 9 8 weeks • Primary objective: Number of patients free from abdominal pain or discomfort
• Greater proportion free from abdominal pain or discomfort at week 8 in PMO group (14/33) vs placebo (6/27) (P < 0.001).
• No significant adverse events reported • No differences in adverse event frequency between groups
Alam
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• Adults with Rome II IBS (n = 74); 9 withdrawals
• Double-blind parallel group study of PMO 2 mL TID (n = 33) vs placebo (n = 32) 9 6 weeks • Primary objective: Assess changes in symptoms and quality of life at 3 week intervals and 2 weeks after treatment completed Unless otherwise indicated data are presented as mean AE standard deviation.
3.3.5 | Peppermint oil effects on colonic physiology (Table 4) Using peppermint oil solution mixed with barium, several investigators have found peppermint oil decreased colonic spasm during barium enema. 57, 58 Investigators also have found that peppermint oil applied topically to the colonic mucosa inhibits colonic motor activity as measured by colonic manometry and ultrasound. 59, 60 Several endoscopy based studies have found peppermint oil (taken orally or administered topically within the colon) decreases colonic peristalsis and/or spasm. [61] [62] [63] [64] Inoue et al found a higher adenoma detection rate during colonoscopy in those receiving peppermint oil vs placebo. 64 In contrast, peppermint oil administered intraluminally potentiated the activity of neostigmine given intramuscularly by further increasing the amplitude of sigmoid contractions in adults. 65 The dose used in this study by Rogers et al was half that used in the study by Duthie et al in which luminal peppermint oil inhibited all sigmoid motor activity following neostigmine injection. 53 
| Peppermint oil usage during endoscopic procedures
As noted above, the anti-spasmodic properties of peppermint oil have been used successfully during both upper GI endoscopies, colonoscopies, and endoscopic retrograde cholangiopancreatography (ERCP) procedures. These studies are summarised in Table 5. 3.5 | Peppermint oil for treatment of gastrointestinal disorders 3.5.1 | Adult irritable bowel syndrome (Table 6) A number of trials have investigated peppermint oil for IBS. As can be seen in Table 6 , the dosing and formulation for peppermint oil varied significantly. All but one study found peppermint oil more effective than placebo in reducing symptoms. 66 Similarly, five peppermint oil meta-analyses have found peppermint oil to be effective in IBS. [67] [68] [69] [70] [71] In the most recent meta-analysis, the number needed to treat was three. 71 It should be noted that given the lack of negative studies there may be potential for publication bias to cause studies showing no benefit to be under-represented in the literature.
3.5.2 | Paediatric functional abdominal pain (Table 7) Two peppermint oil randomised controlled paediatric trials have been carried out, both suggesting benefit. The study by Kline et al was a double blind, randomised, placebo controlled trial that included children with both IBS and functional abdominal pain (J. Kline, 5/ 2007, personal communication). 72 The other trial was randomised and single blinded comparing peppermint oil to a probiotic and folic acid (presumably as a placebo).
72,73
3.5.3 | Functional dyspepsia (Table 8) A number of randomised controlled trials have shown peppermint oil to be effective for functional dyspepsia when used in conjunction with other natural products (primarily caraway). [74] [75] [76] [77] However, to our knowledge, peppermint oil has not been studied alone in a ran- | 747 operative nausea. 78 Peppermint oil aromatherapy was superior to placebo for post-operative nausea following caesarian section. 79 However, two randomised double-blind trials did not find peppermint oil aromatherapy to be superior to saline or controlled breathing for post-operative nausea. • Adults with functional dyspepsia (n = 120); 2 withdrawals
• Double-blind randomised 4 week study comparing PMO/Caraway oil (90 mg/50 mg) (n = 60) vs cisapride (10 mg tid) (n = 58) 9 4 weeks • Primary objective: Mean reduction in pain score using a visual analogue scale
• No significant differences between groups (4.6 vs 4.6)
• Frequency of adverse events similar; PMO, n = 12; cisapride, n = 14
May (2000) 76 • Adults with functional dyspepsia (n = 96)
• Double-blind randomised trial comparing PMO/Caraway oil () vs placebo 9 28 days • Primary outcome was intra-individual change in pain intensity; sensation of pressure, heaviness, and fullness; global improvement using a clinical global impressions item 2) on day 29
• Average intensity of pain was reduced further relative to baseline in the PMO/Caraway oil group vs placebo (40% vs 22%, P < 0.005)) • Sensation of pressure, heaviness, and fullness was reduced further relative to baseline in the PMO/ Caraway oil group vs placebo (43% vs 20%, P < 0.005) • Using CGI item 2, more patients receiving PMO/Caraway oil vs placebo were described as much or very much improved (67% vs 21%, P < 0.005).
• PMO adverse events unattributed to study drug, n = 5
Madisch
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• Adults with functional dyspepsia
• 83 In contrast, mice were more resistant to the effects than were rats with doses of 300 mg kg À1 d À1 of pulegone required to see hepatic injury at 2 weeks. 83 The European Medicines Agency statement points out that "prevailing opinion is that no certain cases of liver toxicity in humans are associated with the use of peppermint oil or mint oil." 42 In a case report of a woman suspected to have ingested peppermint oil in a suicide attempt, although comatose on arrival, she recovered without evidence of hepatic or renal injury. 84 In a 2-year study in rats, pulegone was associated with an increased risk of bladder cancer at a 150 mg kg À1 d À1 dose. In contrast, in a 2-year study of mice, an increased risk for hepatoblastoma was found at the 75 mg kg À1 d
À1
dose but not at the 150 mg kg À1 d À1 dose in males with no increased risk in females. 83 The European Medicines Agency statement posits that "non-relevance of rodent neoplasms to human carcinogenesis seems probable" in part, because of the long-term sustained exposure required and doses which are not relevant in human situations.
The amount of pulegone in peppermint oil can be reduced depending on how the peppermint is grown, when it is harvested, and how it is processed. 85 Peppermint oil normally contains a maximum of 0.1% pulegone and its metabolite menthofuran according to the European Pharmacopoeia (and more commonly 0.03%-0.07%).
The European Medicines Agency statement proposes a lifelong exposure acceptable dose of 0.75 mg kg À1 d
. 42 As likely would be used to treat functional gastrointestinal disorders (oral use for <1 year or intermittently over several years) in adults, the European Medicines Agency statement proposes an acceptable exposure of pulegone plus menthofuran to be 75 mg/d. 42 The maximum usual • Aromatherapy comparing three groups: peppermint spirits inhalation (n = 22) vs placebo inhalation (n = 8) vs standard antiemetic therapy (n = 5) • Primary objective was nausea severity at 2 and 5 min after intervention using a six point nausea scale
• Greater proportion of participants in the peppermint spirits group had no nausea or only slight nausea at 2 min vs placebo (14 (63.6%) vs 0) and vs standard antiemetics (0).
• Greater proportion of participants in the peppermint spirits group had no nausea or only slight nausea at 5 min vs placebo (17 (77.2%) vs 0) and vs standard antiemetics (0).
• Not reported Hunt (2013) • Adults with nausea after ambulatory surgery (n = 303); 2 withdrawals
• Randomised trial of aromatherapy of three groups: 1) essential oil of ginger (n = 76); 2) blend of ginger, spearmint, peppermint, and cardamom oils (n = 74); 3) isopropyl alcohol (n = 78); 4) saline (n = 73) • Primary objective: Reduction in post-operative nausea using a 0-3 scale at 5 min.
• More subjects had an improvement in nausea with the aromatherapy blend vs saline 
